Our Blog

Noxopharm (ASX:NOX) DARRT-1 program in prostate cancer

03 Dec 2019 – Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company’s Phase 1b clinical DARRT-1 trial for its lead product candidate, Veyonda, with low-dose radiotherapy.


Source: Finance News Network

Share this post